HTR3A
5-hydroxytryptamine receptor 3A
As of the edition of 20 October 2026, HTR3A (5-hydroxytryptamine receptor 3A, UniProt P46098) has 20 drugs tested at it and 31 companies on the list, 5 on route A and 8 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P46098
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Mental health; Cancer; Digestive system; Nervous system; Chemically induced; Heart and blood vessels; Blood and lymph; Immune system
- Registered trials of its drugs
- 602
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 8 |
| Active | 2 |
| Went quiet | 7 |
| Stopped | 1 |
| Status not established | 2 |
| Total | 20 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ondansetron | Marketed | Phase 4 | none listed |
| Palonosetron | Marketed | Phase 4 | none listed |
| Vortioxetine | Marketed | Phase 4 | Ends 2031 |
| Granisetron | Marketed | Phase 4 | none listed |
| Ramosetron | Marketed | Phase 4 | none listed |
| Mosapride | Active | Phase 4 | none listed |
| Tropisetron | Active | Phase 4 | none listed |
| Dolasetron | Marketed | Phase 3 | none listed |
| Alosetron | Marketed | Phase 4 | none listed |
| Facinicline | Went quiet | Phase 2 | none listed |
| Pumosetrag | Went quiet | Phase 3 | none listed |
| Azasetron | Status not established | Phase 2 | none listed |
12 of 20 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 8 |
| Engaged | 12 |
| Undetermined | 6 |
| Total on the list | 31 |
| Company | Route |
|---|---|
| Astellas | Route B |
| Helsinn Healthcare | Route B |
| Roche | Route B |
The other 28 companies at HTR3A
In the product31 companies in all; 28 are not named here, and no score is.
See the 31 companies at HTR3A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.